Jump Financial LLC Purchases New Shares in Enovis Corporation $ENOV

Key Points

• Jump Financial LLC acquired 31,703 shares of Enovis Corporation, valued at approximately $1,211,000, indicating institutional interest in the company.
• Several analysts lowered their target prices for Enovis, with the consensus target now at $51.00, while maintaining a "Buy" rating.
• Enovis reported earnings per share of $0.79 for the last quarter, surpassing estimates, with revenues increasing by 7.5% year-over-year.

Jump Financial LLC purchased a new stake in Enovis Corporation (NYSE:ENOV - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,703 shares of the company's stock, valued at approximately $1,211,000. Jump Financial LLC owned approximately 0.06% of Enovis as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC raised its holdings in shares of Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock valued at $27,000 after acquiring an additional 536 shares in the last quarter. Quarry LP raised its holdings in shares of Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 749 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after acquiring an additional 692 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company's stock valued at $74,000 after acquiring an additional 725 shares in the last quarter. Finally, McIlrath & Eck LLC purchased a new stake in shares of Enovis in the 4th quarter valued at about $152,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Trading Down 0.7%

Shares of ENOV stock traded down $0.22 during trading hours on Wednesday, reaching $30.62. The company's stock had a trading volume of 136,833 shares, compared to its average volume of 1,180,788. The stock has a market capitalization of $1.75 billion, a P/E ratio of -2.16 and a beta of 1.68. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83. The firm's fifty day simple moving average is $30.06 and its 200 day simple moving average is $33.37. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.05. The firm had revenue of $564.50 million for the quarter, compared to analyst estimates of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Insider Buying and Selling

In other Enovis news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the transaction, the chief financial officer owned 116,729 shares in the company, valued at $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Bradley J. Tandy purchased 3,200 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the transaction, the senior vice president directly owned 43,515 shares of the company's stock, valued at $1,366,806.15. This represents a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ENOV shares. JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a report on Friday, August 8th. UBS Group decreased their price objective on Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Evercore ISI decreased their price objective on Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Needham & Company LLC decreased their price objective on Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $51.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.